Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fremanezumab in episodic cluster headache
NCT02945046Phase 3Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2017
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of fremanezumab in Cluster Headache (CH) (3 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Mean Change From Baseline in the Weekly Average Number of Cluster Headache (CH) Attacks During the 4-Week Period After Administration of the First Dose of the IMP. Started Jan 2017; status: terminated.
02
Drugs
fremanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT02945046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02945046.